Health Condition 1: C343- Malignant neoplasm of lower lobe,bronchus or lung Health Condition 2: C340- Malignant neoplasm of main bronchus Health Condition 3: C342- Malignant neoplasm of middle lobe,bronchus or lung Health Condition 4: C348- Malignant neoplasm of overlappingsites of bronchus and lung Health Condition 5: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 6: C341- Malignant neoplasm of upper lobe,bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Intramural Fund, MAHE, Manipal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Lung cancer patients (both males and females) with EGFR positive mutation. 2. Patients who are 18 years and above. 3. Patients who are willing to give informed consent. 4. Controls: Individuals (18 years and above) without lung cancer who are willing to take part in the study.
Exclusion criteria
Exclusion criteria: 1. HIV positive patients. 2. Patients with seriously ill conditions or clinically unstable patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study aims to provide an overview of the association of NAT2 gene polymorphisms towards lung cancer susceptibility in a tertiary care hospital. The current study explores the association of CYP2D6 gene polymorphisms with gefitinib-induced toxicities in lung cancer patients.Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Current study could help in deriving individualized drug dosing strategies for improving treatment outcomes, reducing ADRs, and therapeutic compliance. This would pave the way for large-scale cancer pharmacogenomic studies to revitalize precision medicine for Indian lung cancer patientsTimepoint: 1 year | — |
Countries
India
Contacts
Public ContactPratheek J
Manipal College of Pharmaceutical Sciences, MAHE, Manipal
Outcome results
None listed